PTEN缺失与挽救性放疗的不良结局相关
本研究基于320例接受挽救性放疗的前列腺癌患者数据库,用组织芯片免疫组化检测PTEN缺失、ERG表达和p53过表达。结果显示PTEN缺失(43%)与更差的无生化复发生存(HR 1.86)和无转移生存(HR 1.89)相关,且在多因素分析中仍为独立不良预后因素。
要点
- PTEN缺失(n=123,43%)与挽救性放疗后更差的无生化复发生存(HR 1.86)和无转移生存(HR 1.89)相关。
- 均匀PTEN缺失与最高的无转移生存风险相关(HR 2.47),多因素分析中仍预测不良无生化复发生存(HR 1.82)和无转移生存(HR 2.08)。
- p53过表达预测更差的无生化复发生存(HR 1.95)和无转移生存(HR 2.79),ERG表达仅与更差的无转移生存相关(HR 1.6)。
核心结论
- 免疫组化检测的PTEN缺失是接受挽救性放疗的前列腺癌患者无生化复发生存和无转移生存的独立不良预后因素。
- 未来试验将确定治疗具有不良分子预后特征的挽救性放疗患者的最佳方法。
研究设计与样本
- 利用一个包含320例接受挽救性放疗且有可用组织和随访的患者的机构数据库。
- 使用组织芯片进行经遗传学验证的免疫组化检测。
- 所有患者接受挽救性放疗,联合或不联合雄激素剥夺治疗。
- 采用单因素和多因素Cox比例风险模型评估分子表型与挽救性放疗后无生化复发生存和无转移生存的关联。
主要发现
- PTEN缺失(n=123,43%)和ERG表达(n=118,39%)在该队列中常见,p53过表达(提示TP53错义突变)不常见(n=21,7%)。
- 单因素分析中,任何PTEN缺失预示更差的无生化复发生存(HR 1.86;95%CI 1.36-2.57)和无转移生存(HR 1.89;95%CI 1.21-2.94),均匀PTEN缺失与最高的无转移生存风险相关(HR 2.47;95%CI 1.54-3.95)。
- p53过表达预测更差的无生化复发生存(HR 1.95;95%CI 1.14-3.32)和无转移生存(HR 2.79;95%CI 1.50-5.19)。
- ERG表达仅与更差的无转移生存相关(HR 1.6;95%CI 1.03-2.48)。
- 调整已知预后特征的多因素分析中,均匀PTEN缺失仍预测不良的无生化复发生存(HR 1.82;95%CI 1.12-2.96)和无转移生存(HR 2.08;95%CI 1.06-4.86)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究受限于回顾性设计和单机构设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Salvage radiation therapy (SRT) is a mainstay of treatment for biochemical relapse following radical prostatectomy; however, few studies have examined genomic biomarkers in this context. OBJECTIVE: We characterized the prognostic impact of previously identified deleterious molecular phenotypes-loss of PTEN, ERG expression, and TP53 mutation-for patients undergoing SRT. DESIGN, SETTING, AND PARTICIPANTS: We leveraged an institutional database of 320 SRT patients with available tissue and follow-up. Tissue microarrays were used for genetically validated immunohistochemistry assays. INTERVENTION: All men underwent SRT with or without androgen deprivation therapy OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Univariable and multivariable Cox-proportional hazard models assessed the association of molecular phenotypes with biochemical recurrence-free (bRFS) and metastasis-free (MFS) survival after SRT. RESULTS AND LIMITATIONS: Loss of PTEN (n = 123, 43%) and ERG expression (n = 118, 39%) were common in this cohort, while p53 overexpression (signifying TP53 missense mutation) was infrequent (n = 21, 7%). In univariable analyses, any loss of PTEN portended worse bRFS (hazard ratio [HR] 1.86; 95% confidence interval 1.36-2.57) and MFS (HR 1.89; 1.21-2.94), with homogeneous PTEN loss being associated with the highest risk of MFS (HR 2.47; 1.54-3.95). Similarly, p53 overexpression predicted worse bRFS (HR 1.95; 1.14-3.32) and MFS (HR 2.79; 1.50-5.19). ERG expression was associated with worse MFS only (HR 1.6; 1.03-2.48). On the multivariable analysis adjusting for known prognostic features, homogeneous PTEN loss remained predictive of adverse bRFS (HR 1.82; 1.12-2.96) and MFS (HR 2.08; 1.06-4.86). The study is limited by its retrospective and single-institution design. CONCLUSIONS: PTEN loss by immunohistochemistry is an independent adverse prognostic factor for bRFS and MFS in prostate cancer patients treated with SRT. Future trials will determine the optimal approach to treating SRT patients with adverse molecular prognostic features. PATIENT SUMMARY: Loss of the PTEN tumor suppressor protein is associated with worse outcomes after salvage radiotherapy, independent of other clinical or pathologic patient characteristics.
引用
- Lee E, Oliveira LD, Dairo O, et al. PTEN Loss Is Associated with Adverse Outcomes in the Setting of Salvage Radiation Therapy. Eur Urol Oncol. 2024. PMID: 38964997. doi:10.1016/j.euo.2024.06.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。